A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty

Phase 2 Completed 38 enrolled Alkahest, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety, tolerability and effect of GRF6021 on clinical recovery parameters in participants undergoing primary hip or knee arthroplasty.

Timeline

Start: 2019-07-12
Primary completion: 2021-01-23
Completion: 2021-03-04

Publications

Gaudilliere B, Xue L, Tsai AS, Gao X, McAllister TN, Tingle M, Porras G, Feinstein I, Feyaerts D, Verdonk F, Sabayev M, Hedou J, Ganio EA, Berson E, Becker M, Espinosa C, Kim Y, Lehallier B, Rawner E, Feng C, Amanatullah DF, Huddleston JI, Goodman SB, Aghaeepour N, Angst MS. Infusion of young donor plasma components in older patients modifies the immune and inflammatory response to surgical tissue injury: a randomized clinical trial. J Transl Med. 2025 Feb 14;23(1):183. doi: 10.1186/s12967-025-06215-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GRF6021	Protein / enzyme biologic	250 ml	Intravenous

Indications

No indication recorded.